John F Gottlieb1,2, Namni Goel3, Shenghao Chen4, Michael A Young5. 1. Department of Psychiatry and Behavioral Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. 2. Chicago Psychiatry Associates, Chicago, IL, USA. 3. Biological Rhythms Research Laboratory, Department of Psychiatry and Behavioral Sciences, Rush University Medical Center, Chicago, IL, USA. 4. Department of Psychology, Florida State University, Tallahassee, FL, USA. 5. Department of Psychology, Illinois Institute of Technology, Chicago, IL, USA.
Abstract
BACKGROUND: Sleep deprivation (SD) is an antidepressant intervention with multiple administration formats that has been investigated primarily with uncontrolled clinical trials and qualitative reviews of the literature. The validity and applicability of these findings to the treatment of bipolar depression (BPD) is uncertain. METHODS: A PRISMA-based systematic review of the literature and meta-analysis were conducted to determine the efficacy of SD in the treatment of BPD and to identify moderator variables that influence response rate. RESULTS: From a sample of 15 studies covering 384 patients, the overall, mean response rate to SD was 47.6% (CI 36.0%, 59.5%). This response rate compared post-SD to pre-SD depression scores, and not to a placebo control condition. Of several potential moderating variables examined, the use of adjunctive pharmacotherapy achieved statistical significance with response rates of 59.4% [CI 48.5, 69.5] for patients using adjunctive medication vs 27.4% [CI 17.8, 39.8] for patients not using adjunctive medication. CONCLUSIONS: This meta-analysis of SD in the treatment of BPD found an overall, response rate of almost 50%, reinforcing earlier estimates of efficacy. The use of adjunctive pharmacotherapy had a statistically significant moderating effect on SD response suggesting that clinical practice should routinely pair these interventions. These findings provide a higher level of evidence supporting the use of SD, especially when used with medication, and should inform future management guidelines for the treatment of BPD.
BACKGROUND: Sleep deprivation (SD) is an antidepressant intervention with multiple administration formats that has been investigated primarily with uncontrolled clinical trials and qualitative reviews of the literature. The validity and applicability of these findings to the treatment of bipolar depression (BPD) is uncertain. METHODS: A PRISMA-based systematic review of the literature and meta-analysis were conducted to determine the efficacy of SD in the treatment of BPD and to identify moderator variables that influence response rate. RESULTS: From a sample of 15 studies covering 384 patients, the overall, mean response rate to SD was 47.6% (CI 36.0%, 59.5%). This response rate compared post-SD to pre-SD depression scores, and not to a placebo control condition. Of several potential moderating variables examined, the use of adjunctive pharmacotherapy achieved statistical significance with response rates of 59.4% [CI 48.5, 69.5] for patients using adjunctive medication vs 27.4% [CI 17.8, 39.8] for patients not using adjunctive medication. CONCLUSIONS: This meta-analysis of SD in the treatment of BPD found an overall, response rate of almost 50%, reinforcing earlier estimates of efficacy. The use of adjunctive pharmacotherapy had a statistically significant moderating effect on SD response suggesting that clinical practice should routinely pair these interventions. These findings provide a higher level of evidence supporting the use of SD, especially when used with medication, and should inform future management guidelines for the treatment of BPD.
Authors: Elaine M Boland; Hengyi Rao; David F Dinges; Rachel V Smith; Namni Goel; John A Detre; Mathias Basner; Yvette I Sheline; Michael E Thase; Philip R Gehrman Journal: J Clin Psychiatry Date: 2017 Sep/Oct Impact factor: 4.384
Authors: Joseph C Wu; John R Kelsoe; Carol Schachat; Blynn G Bunney; Anna DeModena; Shahrokh Golshan; J Christian Gillin; Steven G Potkin; William E Bunney Journal: Biol Psychiatry Date: 2009-04-09 Impact factor: 13.382
Authors: Lewis L Judd; Pamela J Schettler; Hagop S Akiskal; Jack Maser; William Coryell; David Solomon; Jean Endicott; Martin Keller Journal: Int J Neuropsychopharmacol Date: 2003-06 Impact factor: 5.176
Authors: Nina Trautmann; Jerome C Foo; Josef Frank; Stephanie H Witt; Fabian Streit; Jens Treutlein; Steffen Conrad von Heydendorff; Maria Gilles; Andreas J Forstner; Ulrich Ebner-Priemer; Markus M Nöthen; Michael Deuschle; Marcella Rietschel Journal: Neuropsychopharmacology Date: 2018-05-17 Impact factor: 7.853